Tag - RVNC

Developments

FDA clears Revance’s DAXXIFY injection for cervical dystonia

The FDA approved the first therapeutic indication for Revance Therapeutics’ (NASDAQ:RVNC) DAXXIFY for injection for the treatment of cervical dystonia in adults. Cervical dystonia is a chronic, debilitating disease in...

August 14, 2023

Markets

Stifel starts Revance Therapeutics at buy; PT $50

Stifel initiated coverage of Revance Therapeutics (NASDAQ:RVNC) with a “buy” rating and $50 target price. The stock closed at $17 on Jan. 28. Revance’s Daxi product represents “one of the first truly novel neurotoxin...

January 29, 2019

Markets

Needham starts Revance Therapeutics at buy; PT $42

Needham initiated coverage of Revance Therapeutics (NASDAQ:RVNC) with a “buy” rating and $42 price target. The stock closed at $30.60 on March 26. Revance is involved in the development of novel and differentiated...

March 27, 2018

Tag - RVNC

FDA clears Revance’s DAXXIFY injection for cervical dystonia

Stifel starts Revance Therapeutics at buy; PT $50

Needham starts Revance Therapeutics at buy; PT $42

General

More